Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2/3 randomized, open-label, controlled, parallel-arm study of Ampligen in patients with advanced or metastatic late-stage pancreatic cancer

Next Previous
Trial Profile

A phase 2/3 randomized, open-label, controlled, parallel-arm study of Ampligen in patients with advanced or metastatic late-stage pancreatic cancer

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 22 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors AIM ImmunoTech

Most Recent Events

  • 19 Oct 2021 According to an AIM ImmunoTech media release, the company has submitted an Investigational New Drug application (IND) and an accompanying application for Fast Track status with the USA Food and Drug Administration (FDA) for this study.
  • 04 Oct 2021 According to an AIM ImmunoTech media release, Prof. Kelsey Klute is the study's principal investigator in the United States.
  • 04 Oct 2021 According to an AIM ImmunoTech media release, the company has finalized the protocol for a planned Phase 2 study and the company expects to submit both an Investigational New Drug application (IND) and an application for Fast Track status with the U.S. Food and Drug Administration (FDA) no later than October 18, 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top